KR20070083705A - 티로신 키나제 수용체 cfms를 억제하기 위한4-(4-메틸피페라진-1-일메틸)-n-[4-메틸-3-(4-(피리딘-3-일)피리미딘-2-일아미노)페닐]-벤즈아미드의 용도 - Google Patents
티로신 키나제 수용체 cfms를 억제하기 위한4-(4-메틸피페라진-1-일메틸)-n-[4-메틸-3-(4-(피리딘-3-일)피리미딘-2-일아미노)페닐]-벤즈아미드의 용도 Download PDFInfo
- Publication number
- KR20070083705A KR20070083705A KR1020077008716A KR20077008716A KR20070083705A KR 20070083705 A KR20070083705 A KR 20070083705A KR 1020077008716 A KR1020077008716 A KR 1020077008716A KR 20077008716 A KR20077008716 A KR 20077008716A KR 20070083705 A KR20070083705 A KR 20070083705A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- fms
- csf
- carcinoma
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61974404P | 2004-10-18 | 2004-10-18 | |
| US60/619,744 | 2004-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070083705A true KR20070083705A (ko) | 2007-08-24 |
Family
ID=36202610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077008716A Ceased KR20070083705A (ko) | 2004-10-18 | 2005-10-17 | 티로신 키나제 수용체 cfms를 억제하기 위한4-(4-메틸피페라진-1-일메틸)-n-[4-메틸-3-(4-(피리딘-3-일)피리미딘-2-일아미노)페닐]-벤즈아미드의 용도 |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| EP3246046A4 (en) * | 2015-01-13 | 2018-12-05 | Kyoto University | Agent for preventing and/or treating amyotrophic lateral sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) * | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| DE60212836T2 (de) * | 2001-05-16 | 2007-01-25 | Gpc Biotech Ag | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
| US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
-
2005
- 2005-10-17 JP JP2007535954A patent/JP2008516898A/ja active Pending
- 2005-10-17 RU RU2007118420/15A patent/RU2007118420A/ru unknown
- 2005-10-17 NZ NZ554009A patent/NZ554009A/en not_active IP Right Cessation
- 2005-10-17 CN CNA2005800338341A patent/CN101035535A/zh active Pending
- 2005-10-17 KR KR1020077008716A patent/KR20070083705A/ko not_active Ceased
- 2005-10-17 DE DE602005025514T patent/DE602005025514D1/de not_active Expired - Lifetime
- 2005-10-17 AU AU2005297321A patent/AU2005297321A1/en not_active Abandoned
- 2005-10-17 BR BRPI0517083-4A patent/BRPI0517083A/pt not_active IP Right Cessation
- 2005-10-17 WO PCT/AU2005/001602 patent/WO2006042362A1/en not_active Ceased
- 2005-10-17 EP EP05793868A patent/EP1804800B1/en not_active Expired - Lifetime
- 2005-10-17 AT AT05793868T patent/ATE492277T1/de not_active IP Right Cessation
- 2005-10-17 US US11/576,967 patent/US20080255139A1/en not_active Abandoned
- 2005-10-17 CA CA002580976A patent/CA2580976A1/en not_active Abandoned
- 2005-10-17 MX MX2007004660A patent/MX2007004660A/es unknown
-
2007
- 2007-03-20 ZA ZA200702316A patent/ZA200702316B/xx unknown
- 2007-04-10 IL IL182419A patent/IL182419A0/en unknown
- 2007-04-17 TN TNP2007000141A patent/TNSN07141A1/fr unknown
- 2007-04-25 MA MA29848A patent/MA28946B1/fr unknown
- 2007-05-15 NO NO20072501A patent/NO20072501L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007118420A (ru) | 2008-11-27 |
| ATE492277T1 (de) | 2011-01-15 |
| MA28946B1 (fr) | 2007-10-01 |
| JP2008516898A (ja) | 2008-05-22 |
| DE602005025514D1 (de) | 2011-02-03 |
| WO2006042362A1 (en) | 2006-04-27 |
| BRPI0517083A (pt) | 2008-09-30 |
| TNSN07141A1 (en) | 2008-11-21 |
| CN101035535A (zh) | 2007-09-12 |
| EP1804800A4 (en) | 2008-03-19 |
| NZ554009A (en) | 2010-09-30 |
| CA2580976A1 (en) | 2006-04-27 |
| US20080255139A1 (en) | 2008-10-16 |
| IL182419A0 (en) | 2007-09-20 |
| MX2007004660A (es) | 2007-10-17 |
| EP1804800A1 (en) | 2007-07-11 |
| ZA200702316B (en) | 2008-09-25 |
| EP1804800B1 (en) | 2010-12-22 |
| AU2005297321A1 (en) | 2006-04-27 |
| NO20072501L (no) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10314834B2 (en) | Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation | |
| Wlodarski et al. | Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum | |
| US8841319B2 (en) | Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management | |
| US20100150844A1 (en) | Use of 8-quinolinol and its analogs to target cancer stem cells | |
| EP1853302A2 (en) | Antiangiogenic agents with aldesleukin | |
| TW201806600A (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| JP7660195B2 (ja) | Csf1rキナーゼ阻害剤およびその使用 | |
| US20250017921A1 (en) | Pharmaceutical combination and tumor treatment | |
| Fraser et al. | Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo | |
| HUP0302913A2 (hu) | Eljárások ráksejt-halál és tumor visszafejlődés indukálására és ezek kezelésére alkalmas gyógyszerkészítmények előállítására | |
| WO2016198698A2 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
| JP2018511605A (ja) | 慢性骨髄性白血病癌幹細胞の成長抑制用または増殖抑制用の組成物、及びそのスクリーニング方法 | |
| JP2024514958A (ja) | ユビキチン特異的ペプチダーゼ22(usp22)の阻害剤、並びに疾患及び障害の治療のためのその使用 | |
| EP1804800B1 (en) | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl¨-benzamide to inhibit the tyrosine kinase receptor c-fms | |
| WO2017090699A1 (ja) | ピラジンカルボキサミド化合物を有効成分とするがん免疫治療用医薬組成物、及び/又は、免疫活性化用医薬組成物 | |
| KR20230110751A (ko) | 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제 | |
| RU2415672C2 (ru) | Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии | |
| US20150141502A1 (en) | Inhibition of leukemic stem cells by pp2a activating agents | |
| JP5931876B2 (ja) | 多発性嚢胞腎を処置するためのレセプタータイプキナーゼの調節因子の使用 | |
| US20240335449A1 (en) | Combination therapy for vav3 cancer | |
| JP2024061699A (ja) | Ras遺伝子変異体癌治療薬 | |
| Hedvat | Targeting JAK/STAT Signaling for Solid Tumor Therapy | |
| US20060106026A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer | |
| Sabio et al. | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
| Brownlow | Kinase inhibitors of the FMS receptor for macrophage colony stimulating factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070417 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20101014 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20120731 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130124 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20120731 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |